JP6833844B2 - アルギナーゼ活性を阻害する組成物及び方法 - Google Patents

アルギナーゼ活性を阻害する組成物及び方法 Download PDF

Info

Publication number
JP6833844B2
JP6833844B2 JP2018522126A JP2018522126A JP6833844B2 JP 6833844 B2 JP6833844 B2 JP 6833844B2 JP 2018522126 A JP2018522126 A JP 2018522126A JP 2018522126 A JP2018522126 A JP 2018522126A JP 6833844 B2 JP6833844 B2 JP 6833844B2
Authority
JP
Japan
Prior art keywords
cancer
use according
compound
tumor
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018522126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533582A5 (OSRAM
JP2018533582A (ja
Inventor
シェーグレン，エリック・ビー
リー，ジム
バン・ザント，マイケル
ホワイトハウス，ダレン
Original Assignee
カリセラ バイオサイエンシズ，インコーポレイテッド
カリセラ バイオサイエンシズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリセラ バイオサイエンシズ，インコーポレイテッド, カリセラ バイオサイエンシズ，インコーポレイテッド filed Critical カリセラ バイオサイエンシズ，インコーポレイテッド
Publication of JP2018533582A publication Critical patent/JP2018533582A/ja
Publication of JP2018533582A5 publication Critical patent/JP2018533582A5/ja
Application granted granted Critical
Publication of JP6833844B2 publication Critical patent/JP6833844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018522126A 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法 Active JP6833844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US62/248,632 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US62/281,964 2016-01-22
US201662323034P 2016-04-15 2016-04-15
US62/323,034 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021014795A Division JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018533582A JP2018533582A (ja) 2018-11-15
JP2018533582A5 JP2018533582A5 (OSRAM) 2020-03-19
JP6833844B2 true JP6833844B2 (ja) 2021-02-24

Family

ID=58631120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018522126A Active JP6833844B2 (ja) 2015-10-30 2016-10-28 アルギナーゼ活性を阻害する組成物及び方法
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021014795A Expired - Fee Related JP7032583B2 (ja) 2015-10-30 2021-02-02 アルギナーゼ活性を阻害する組成物及び方法
JP2022025334A Withdrawn JP2022071010A (ja) 2015-10-30 2022-02-22 アルギナーゼ活性を阻害する組成物及び方法

Country Status (36)

Country Link
US (4) US10065974B2 (OSRAM)
EP (3) EP3693375B1 (OSRAM)
JP (3) JP6833844B2 (OSRAM)
KR (2) KR102434308B1 (OSRAM)
CN (4) CN113201002A (OSRAM)
AU (3) AU2016343656B2 (OSRAM)
BR (3) BR112018008746B1 (OSRAM)
CA (1) CA3003271A1 (OSRAM)
CL (4) CL2018001134A1 (OSRAM)
CO (1) CO2018004750A2 (OSRAM)
CR (3) CR20180282A (OSRAM)
CY (1) CY1123557T1 (OSRAM)
DK (2) DK4011887T3 (OSRAM)
EA (1) EA038276B1 (OSRAM)
EC (1) ECSP18040250A (OSRAM)
ES (3) ES2991555T3 (OSRAM)
HR (1) HRP20201046T1 (OSRAM)
HU (1) HUE054972T2 (OSRAM)
IL (3) IL258731B (OSRAM)
LT (1) LT3368541T (OSRAM)
MA (2) MA50636A (OSRAM)
MD (1) MD3368541T2 (OSRAM)
MX (1) MX2018005294A (OSRAM)
MY (1) MY201783A (OSRAM)
NZ (1) NZ742742A (OSRAM)
PH (2) PH12018500899B1 (OSRAM)
PL (1) PL3368541T3 (OSRAM)
PT (1) PT3368541T (OSRAM)
RS (1) RS60695B1 (OSRAM)
SG (4) SG10201911402YA (OSRAM)
SI (1) SI3368541T1 (OSRAM)
SM (1) SMT202000469T1 (OSRAM)
TW (3) TWI710565B (OSRAM)
UA (1) UA125289C2 (OSRAM)
WO (1) WO2017075363A1 (OSRAM)
ZA (4) ZA201803556B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514271A (ja) * 2016-12-22 2020-05-21 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物及び方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
TWI710565B (zh) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CA3042878A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
BR112019023582A2 (pt) 2017-05-12 2020-06-02 Calithera Biosciences Inc. Método de preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CA3091365A1 (en) 2018-02-17 2019-08-22 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EA202092086A1 (ru) 2018-03-05 2021-02-09 Аркус Байосайенсиз, Инк. Ингибиторы аргиназы
WO2019177873A1 (en) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
PL3774843T3 (pl) 2018-03-29 2022-11-14 Molecure Sa Dipeptydowe pochodne piperydyny
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
AU2019379808C1 (en) 2018-11-16 2024-01-25 Arcus Biosciences, Inc. Inhibitors of ARG1 and/or ARG2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020131598A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN113614095B (zh) * 2019-02-06 2024-08-23 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
US11420966B2 (en) * 2019-05-02 2022-08-23 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
JP7579324B2 (ja) * 2019-07-23 2024-11-07 アストラゼネカ・アクチエボラーグ アルギナーゼ阻害剤及びその使用方法
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SI4175719T1 (sl) 2020-07-02 2025-07-31 Incyte Corporation Triciklične sečninske spojine kot zaviralci jak2 v617f
TW202216662A (zh) * 2020-07-17 2022-05-01 美商英塞特公司 製備精胺酸酶抑制劑及其合成中間物之方法
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202416968A (zh) 2022-10-21 2024-05-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
CN121079299A (zh) 2023-03-13 2025-12-05 因赛特公司 作为激酶抑制剂的双环脲

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US6403609B1 (en) 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
WO2002004465A1 (en) 2000-07-06 2002-01-17 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DE602004023516D1 (de) 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
KR20100080798A (ko) * 2007-10-12 2010-07-12 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
HUE046932T2 (hu) * 2009-01-26 2020-04-28 Univ Pennsylvania Argináz inhibitorok és felhasználási eljárások
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
ES2568680T3 (es) * 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
BR112014009531A8 (pt) 2011-10-20 2018-01-16 Glaxosmithkline Llc aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína
WO2013158262A1 (en) 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
CN111329989A (zh) * 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
AU2014339816B2 (en) * 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
EP3270907A1 (en) * 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
MX385315B (es) * 2015-06-23 2025-03-14 Calithera Biosciences Inc Composiciones y metodos para inhibir actividad de arginasa.
TWI710565B (zh) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514271A (ja) * 2016-12-22 2020-05-21 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物及び方法
JP7018949B2 (ja) 2016-12-22 2022-02-14 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物及び方法
US12054501B2 (en) 2016-12-22 2024-08-06 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity

Also Published As

Publication number Publication date
ZA201907093B (en) 2021-03-31
BR112018008746A2 (pt) 2018-10-30
JP7032583B2 (ja) 2022-03-08
CA3003271A1 (en) 2017-05-04
TWI710565B (zh) 2020-11-21
BR112018008746B1 (pt) 2021-11-16
KR20220118559A (ko) 2022-08-25
DK4011887T3 (da) 2024-10-28
ES2991555T3 (es) 2024-12-04
PT3368541T (pt) 2020-07-06
IL288225A (en) 2022-01-01
EP3368541A1 (en) 2018-09-05
MA50636A (fr) 2021-04-14
US10851118B2 (en) 2020-12-01
SG10201911406TA (en) 2020-01-30
US20180346489A1 (en) 2018-12-06
IL281503A (en) 2021-04-29
CR20210390A (es) 2021-10-19
CN108271371A (zh) 2018-07-10
CL2019000820A1 (es) 2019-08-09
CL2018001134A1 (es) 2018-10-26
CN113150016A (zh) 2021-07-23
PH12022551082A1 (en) 2023-03-13
CN108271371B (zh) 2021-02-09
CR20180282A (es) 2018-11-30
AU2016343656A1 (en) 2018-06-07
IL258731B (en) 2021-04-29
EP4011887B1 (en) 2024-07-31
EP3693375B1 (en) 2022-02-16
US10065974B2 (en) 2018-09-04
HRP20201046T1 (hr) 2020-10-16
CR20210389A (es) 2021-09-16
ZA201803556B (en) 2021-02-24
MA43131B1 (fr) 2020-07-29
EP3693375A1 (en) 2020-08-12
WO2017075363A1 (en) 2017-05-04
SMT202000469T1 (it) 2020-11-10
ECSP18040250A (es) 2018-10-31
ZA201907092B (en) 2021-04-28
EA038276B1 (ru) 2021-08-04
BR122020022275B1 (pt) 2022-05-03
SG10201911402YA (en) 2020-02-27
SI3368541T1 (sl) 2020-10-30
CN113150015A (zh) 2021-07-23
JP2018533582A (ja) 2018-11-15
CL2019000821A1 (es) 2019-08-09
LT3368541T (lt) 2020-09-25
MX2018005294A (es) 2018-09-21
MD3368541T2 (ro) 2020-09-30
BR112018008746A8 (pt) 2019-02-26
EP4011887A1 (en) 2022-06-15
PH12018500899A1 (en) 2018-10-29
AU2020286278B2 (en) 2022-03-17
TWI775556B (zh) 2022-08-21
TWI734630B (zh) 2021-07-21
EA201891057A1 (ru) 2018-12-28
US20200223872A1 (en) 2020-07-16
TW202146028A (zh) 2021-12-16
AU2016343656B2 (en) 2020-09-17
ES2808988T3 (es) 2021-03-02
CL2019000819A1 (es) 2019-08-09
TW202110858A (zh) 2021-03-16
SG11201802961PA (en) 2018-05-30
PH12018500899B1 (en) 2023-02-08
ZA201907091B (en) 2021-05-26
US20170121352A1 (en) 2017-05-04
HK1252560A1 (en) 2019-05-31
CY1123557T1 (el) 2022-03-24
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
AU2020286278A1 (en) 2021-01-14
KR20180084063A (ko) 2018-07-24
IL258731A (en) 2018-06-28
CO2018004750A2 (es) 2018-10-31
EP3368541B1 (en) 2020-05-27
TW201726692A (zh) 2017-08-01
PL3368541T3 (pl) 2020-11-02
DK3368541T3 (da) 2020-06-29
BR122020022280B1 (pt) 2022-05-03
KR102434308B1 (ko) 2022-08-19
US10844080B2 (en) 2020-11-24
ES2910928T3 (es) 2022-05-17
MY201783A (en) 2024-03-18
JP2022071010A (ja) 2022-05-13
CN113201002A (zh) 2021-08-03
UA125289C2 (uk) 2022-02-16
JP2021075543A (ja) 2021-05-20
US20210061822A1 (en) 2021-03-04
IL281503B (en) 2022-01-01
HUE054972T2 (hu) 2021-10-28
AU2022203703A1 (en) 2022-06-16
RS60695B1 (sr) 2020-09-30
EP3368541A4 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
JP7018949B2 (ja) アルギナーゼ活性を阻害するための組成物及び方法
HK1252560B (en) Compositions and methods for inhibiting arginase activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210203

R150 Certificate of patent or registration of utility model

Ref document number: 6833844

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250